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The efficacy of a thromboxane synthetase inhibitor (U- 
63,557A, Upjohn) in promoting early patency and in- 
hibiting anastomotic intimal hyperplasia in ePTFE grafts 
was compared to that of acetylsalicylic acid (ASA) in a 
canine model. Animals were started on ASA 5 gr po qd 
(Group I, n = 12) or U-63,557A 10 mg/kg po bid (Group 
II, n = 12) 1 day before placement of bilateral 5-mm-i.d., 
13- to 16.5-cm-long ePTFE aortoiliac grafts and contin- 
ued on the medication for the 16-week study. Six dogs 
in each group received autologous endothelial cell-seeded 
grafts, while the other six received unseeded grafts. Pa- 
tency was determined weekly by assessment of femoral 
pulses. At the conclusion of the study anastomotic intimal 
hyperplasia was measured on serial sections through the 
distal anastomosis using a computer-linked digitizer. In 
Group I the patencies of seeded and unseeded grafts were 
not significantly different, being 100 and 83%, respec- 
tively. Furthermore, luminal narrowing due to intimal 
hyperplasia was not significantly different being 9.1 
f 7.6% (x + SD) in seeded grafts and 8.8 f 8.1% in un- 
seeded grafts. On the other hand, in Group II the seeded 
grafts had significantly improved patency when com- 
pared to the unseeded grafts (83% vs 33%, P < 0.05) and 
less luminal narrowing (11.4 + 11.1% vs 21.9 * 19.5%, 
P < 0.01). Although U-63,557A administration pro- 
moted patency of unseeded grafts compared to no anti- 
platelet medication (0% patency), it was significantly less 
effective than ASA in improving patency (P < 0.05) and 
inhibiting luminal narrowing (P < 0.01). o 1989 Academic 
Press, Inc. 
INTRODUCTION 
Research continues to be directed at the development 
a small caliber prosthetic graft with an acceptable patency 
rate in peripheral arterial reconstructions. Low patency 
rates are attributed to early occlusion due to the throm- 
1 To whom correspondence should be addressed at Veterans Admin- 
istration Medical Center, 10701 East Boulevard, Cleveland, OH 44106. 
bogenicity of the graft surface and late failure due to 
anastomotic intimal hyperplasia. Many experimental 
studies have demonstrated the efficacy of pharmacologic 
agents such as anticoagulant or antiplatelet drugs in pro- 
moting early patency. However, the role of antiplatelet 
agents in promoting long-term patency by reducing anas- 
tomotic hyperplasia remains to be clarified. 
Endothelial cell (EC) seeding of prosthetic grafts pro- 
motes the early development of an endothelial lining and 
improves the patency of small caliber grafts in experi- 
mental animals [l, 6,10,21]. Such endothelial cell linings 
have been shown to be functionally intact as evidenced 
by production of prostacyclin as well as by decreased 
graft-platelet interactions [4, 221. Canine studies using 
large caliber grafts have demonstrated the ability of EC 
seeding to reduce the midgraft inner capsule thickness 
compared to unseeded grafts [3]. However, the effect of 
seeding on anastomotic hyperplasia is uncertain. The 
usefulness of EC seeding and antiplatelet agents in pro- 
moting and reducing anastomotic intimal hyperplasia has 
been the subject of recent investigations in our laboratory. 
This report describes the results of studies of anastomotic 
hyperplasia in EC-seeded and unseeded grafts in animals 
receiving U-63,557A, a thromboxane synthetase inhibitor 
which has the theoretical advantage of not inhibiting 
prostacyclin (PGI& production by the EC. The patency 
data from this study has been previously published [ 111. 
The “control” animals receiving acetylsalicylic acid (ASA) 
are part of a multiarm study, part of which has been pre- 
viously published [ 121. 
MATERIALS AND METHODS 
Patency rate and degree of anastomotic intimal hyper- 
plasia were studied in bilateral aortoiliac expanded poly- 
tetrafluoroethylene (ePTFE) grafts, 5 mm in i.d., 13 to 
16.5 cm long, implanted in adult mongrel dogs weighing 
19 to 38 kg. Standard, thin-walled, ePTFE grafts (donated 
by W. L. Gore and Associates, Flagstaff, AR) were used. 
These grafts were characterized by nodes of PTFE with 
longitudinally oriented, interconnecting fibrils having 
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nominal lengths of 30 pm, and a dense, outer circumfer- 
ential wrap of ePTFE. Two grafts seeded with autologous 
endothelial cells or two unseeded grafts were implanted 
in each dog. This procedure was utilized to prevent cross 
contamination of EC as well as to avoid any adverse sys- 
temic effects of one type of graft on the other in dogs 
receiving both seeded and unseeded prostheses. Dogs were 
cared for at the Ann Arbor Veterans Administration 
Medical Center Animal Research Facility which is ac- 
credited by the American Association for Accreditation 
of Laboratory Animal Care. Surgical procedures and an- 
imal care complied with the standards in The Guide for 
the Care and Use of Laboratory Animals (DHEW Publi- 
cation No. (NIH) 78-23, revised, 1978). 
Two different antiplatelet agents were evaluated. Group 
I dogs (n = 12) received ASA 5 gr po qd. Group II animals 
(n = 12) received an oral thromboxane synthetase inhib- 
itor (sodium 5-(3’-pyridinylmethyl)benzofuran-2-car- 
boxylate), U-63,557A (The Upjohn Co., Kalamazoo, MI), 
10 mg/kg po bid. Drug administration began 1 day prior 
to surgery and continued for the entire 16-week study. 
Hematologic and coagulation parameters, including 
white blood count, platelet count, activated partial 
thromboplastin time, thrombin time, and fibrinogen lev- 
els, were studied in all animals. In addition, platelet ag- 
gregation in response to ADP, thrombin, and collagen 
was measured. Animals were paired on the basis of sim- 
ilarity of these parameters. 
Anesthesia was induced with thiamylal sodium and 
maintained with halothane/N20/02 using mechanical 
ventilation. Penicillin G benzathine and procaine hydro- 
chloride (450,000 IU each) were administered preopera- 
tively. Animals were hydrated with lactated Ringer’s so- 
lution (15 ml/kg/hr) throughout the operation. A IO-cm 
segment of external jugular vein was removed for the har- 
vest of autologous endothelial cells. The excised vein was 
everted over a 5-mm stainless steel rod and incubated for 
10 min at 37’C in 0.1% trypsin in Ca2+- and M2+-free 
Hanks’ balanced salt solution (BSS) containing 0.125% 
EDTA at pH 8.0. The vein was then immersed in colla- 
genase (Worthington, CLS Type I, activity 630 U/ml) in 
Hanks’ BSS with Ca2+ and Mg2+ at pH 7.3 for 10 min at 
37°C. A pellet containing an average of 8 X lo5 endothelial 
cells (range, 0.4 to 1.5 X 106) was obtained by centrifu- 
gation and resuspended in culture medium. While the in- 
frarenal aorta and distal iliac arteries were exposed 
through a midline abdominal incision, the grafts were 
filled with autologous blood and incubated for 30 min. 
After evacuation of this blood, the grafts were flushed 
with 5 ml of blood containing 1000 IU heparin sodium. 
Each experimental graft was then filled with half of the 
EC suspension and allowed to incubate for 15 min, while 
the graft was rotated every 5 min. Unseeded control grafts 
underwent identical preparation, except that endothelial 
cells were not added to the culture medium. After prep- 
aration, grafts were placed in a retroperitoneal tunnel be- 
tween the aorta and external iliac arteries. Animals were 
systemically anticoagulated with intravenous heparin so- 
dium (100 III/kg). After clamping the infrarenal aorta, 
lateral aortotomies were made and end-to-side anasto- 
moses were created between each graft and the aorta using 
6-O polypropylene suture. Care was taken to assure that 
the second aortotomy corresponded precisely to the first, 
thereby avoiding asymmetrical anastomotic hemody- 
namic effects. Clamps were then placed on both distal 
iliac arteries and an end-to-side anastomosis was com- 
pleted between each graft and iliac artery using continuous 
6-O polypropylene suture. Blood flow was established 
through both grafts simultaneously. The anticoagulant 
effect of the heparin was reversed with intravenous ad- 
ministration of protamine sulfate (1.0 mg/kg). The me- 
dian sacral artery and the iliac arteries proximal to the 
distal anastomoses were ligated with 0 silk to assure that 
flow was directed through the grafts. A completion aor- 
togram was performed in all animals to identify and im- 
mediately correct any technical problems. 
Graft patency was determined by assessment of femoral 
artery pulses three times a week for the first 2 weeks and 
weekly thereafter. Patency rates of seeded and unseeded 
grafts were compared using the X2 test. The study was 
continued for a total of 16 weeks except in instances of 
bilateral graft occlusion after which the prostheses were 
removed immediately. Weekly serum thromboxane levels 
were determined for Group II dogs. Immediately prior to 
the morning dose of U-63,557A, blood samples were drawn 
into cold syringes containing 0.2 mg ASA. Serum samples 
were frozen and stored at -70°C until radioimmunoassay 
for the stable metabolite, thromboxane B2 (TXB2) [8], 
was performed at the University of Michigan Medical 
Center Ligand Laboratory of the Diabetes Research and 
Training Center. 
At the time of sacrifice, animals were anesthetized and 
the aorta, left renal artery, and iliofemoral arterial systems 
were isolated. Heparin sodium (150 IU/kg) was admin- 
istered intravenously, and an infusion catheter was placed 
in the left renal artery with outflow cannulae inserted 
into both femoral arteries. The vessels and grafts were 
flushed with phosphate-buffered saline solution until the 
effluent was clear. The infrarenal aorta, aortoiliac grafts, 
and proximal femoral arteries were then excised. The 
midsection of one graft was filled with Hanks’ BSS and 
incubated for 5 min for determination of prostacyclin and 
thromboxane production. Prostanoid production was 
similarly measured in a portion of excised distal aorta by 
radioimmunoassay of the stable degradation products, 6- 
keto-PGFi, and TXB2. Prostanoid production was com- 
pared using the unpaired t test. The midportion of each 
graft was split longitudinally, with one-half being pro- 
cessed for light microscopy and the other half for scanning 
electron microscopy. Anastomotic regions were fixed in 
glutaraldehyde, dehydrated in ethanol, embedded in glycol 
methacrylate, sectioned at 2-mm intervals perpendicular 
to the long axis of the anastomosis, and stained with 
methylene blue-basic fuchsin for light microscopic anal- 
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ysis (Fig. 1). Using a computer-linked digitizer the cir- 
cumference of the artery and graft was measured at the 
intima-media and inner capsule-graft junction allowing 
calculation of the area of the original lumen. The area of 
intimal hyperplasia and inner capsule thickening was 
measured, and the percentage of luminal narrowing was 
calculated. Anastomotic hyperplasia (intimal hyperplasia 
of the artery plus inner capsule thickening of the graft) 
in various groups was compared using the unpaired t test. 
RESULTS 
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Serum thromboxane levels in Group II animals aver- 
aged at least 30% below preoperative baseline values. This 
measurement was obtained when serum concentration of 
U-63,557A was at its trough level. 
In seeded grafts of Group I, 12 of 12 (100%) grafts re- 
mained patent for the entire 16-week study, while 9 of 12 
(75%) unseeded grafts remained patent (Fig. 2). This ap- 
proached statistical significance, P = 0.06. In Group II, 
10 of 12 (83%) seeded grafts were patent at 16 weeks, 
compared to only 4 of 12 (33%) unseeded grafts. This was 
significantly different, P < 0.05. In Group I, all occlusions 
of the unseeded grafts occurred late (after 4 weeks post- 
implantation) in the study period. However, in Group II 
one of the occlusions of seeded grafts occurred early (be- 
fore 4 weeks after implantation), while the other occurred 
late. In the unseeded grafts of Group II, two occlusions 
occurred early and the remaining six occurred at or after 
4 weeks following graft placement. On macroscopic ex- 
amination most graft occlusions which occurred after the 
first 4 weeks appeared to be due to accumulation of tissue 
at the distal anastomosis. 
Inner Capsule 
lntimal 
Hyperplasia 
FIG. 1. Serial sections were taken at 2-mm intervals through the 
distal anastomosis. The area of the inner capsule and intimal hyperplasia 
was measured using a computer-linked digitizer. 
ASA U-63,557A 
FIG. 2. In dogs receiving ASA the 16-week patency rate was 100% 
in seeded grafts compared to 75% in unseeded grafts (P = 0.06). In 
animals receiving U-63,557A the 16-week patency rate was 83% in seeded 
grafts compared to 33% in unseeded grafts (P < 0.05). 
Luminal production of prostacyclin was significantly 
greater (P < 0.05) in seeded grafts than in unseeded grafts 
of Group I (Table 1). However, both values were markedly 
less than aortic production. In Group II animals, the dif- 
ference in PGIr production between seeded grafts and un- 
seeded grafts did not reach statistical-significance, but 
again both values were distinctly less than PGIz produc- 
tion by the aorta. Thromboxane production by seeded 
grafts in Groups I and II was not significantly different 
from that in unseeded grafts or aorta. 
Histologic studies revealed a cellular lining covering 
approximately 50% of the midportion of seeded grafts. 
This had the appearance of endothelium on scanning 
electron microscopy (SEM). Cells with the appearance of 
endothelium were rarely seen away from the anastomotic 
regions in unseeded grafts, covering less than 10% of the 
surface area. Interestingly, in one Group I dog with un- 
seeded grafts, endothelium lined approximately 40% of 
each graft. 
Measurements of intimal hyperplasia at the distal 
anastomosis demonstrated no significant difference be- 
tween seeded and unseeded grafts in Group I (Table 2). 
Luminal compromise due to the inner capsule of the graft 
TABLE 1 
Luminal Production of PGIz and TXBz (pg/cm2/5 min) 
PGIp TXBs 
ASA 
EC-seeded graft 70 f 50 24 + 20 
Unseeded graft 19 f 12 23 f 56 
Aorta 760 f 1236 132 f 229 
U-63,557A 
EC-seeded graft 834 + 482 1248 f 1862 
Unseeded graft 687 _+ 241 2991 f 4282 
Aorta 4318 * 5955 577 f 566 
Note. Values are means f SDS. 
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TABLE 2 
Luminal Narrowing Due to Anastomotic Hyperplasia 
Treatment Seeded grafts Unseeded grafts 
ASA 
U-63,557A 
9.12 7.6% 8.8 zt 8.1% 
1 -nsI 1 
P = 0.07 P < 0.01 
I 
11.4 * 11.1% 21.9 f 19.5% 
-p<o.o1- 
Note. Values are means f SDS. 
and to intimal hyperplasia at the anastomosis was not 
significantly different in seeded grafts (9.1 _+ 7.6%) com- 
pared to that in unseeded grafts (8.8 + 8.1%). However, 
in Group II the luminal narrowing in seeded grafts (11.4 
-t 11.1%) was significantly less than that in unseeded 
grafts (21.9 -+ 19.5%), P < 0.01. When comparing Groups 
I and II, the difference in luminal narrowing at the anas- 
tomoses of seeded grafts approached significance, P 
= 0.07, but in unseeded grafts was clearly significantly 
less, P < 0.01, in Group I. 
DISCUSSION 
This investigation was undertaken to evaluate the effect 
of various antiplatelet drugs and EC seeding on prevention 
of graft failure due to early thrombosis and later devel- 
opment of anastomotic intimal hyperplasia. The aortoiliac 
model was selected to allow study of hyperplasia at an 
end-to-side anastomosis. Previous studies in our labora- 
tories had demonstrated that the patencies of seeded and 
unseeded small caliber grafts were similar if no antiplate- 
let agents were utilized to inhibit thrombosis until an en- 
dothelial cell surface had developed [lo, 211. However, 
with the perioperative use of acetylsalicylic acid and di- 
pyridamole, EC seeding significantly improved that 16- 
week patency rate of 4-mm-i.d. ePTFE aortoiliac grafts 
from 0% for control grafts to 50% for seeded grafts [lo]. 
Since evaluation of anastomotic hyperplasia requires the 
patency of some control grafts, 5-mm ePTFE grafts were 
used in the present study. 
A thromboxane synthetase inhibitor was selected for 
comparison with ASA with the expectation that continued 
PG12 production by EC-seeded grafts would prove bene- 
ficial in promoting long-term patency. As anticipated, 
PGIz production by the graft and aortic surface was 
greater in U-63,557A animals than in ASA-treated dogs. 
However, TXBp production was also greater in U-63,557A 
animals. The reason for this is uncertain and may be a 
reflection of the short half-life of U-63,557A since dogs 
were sacrificed 15 to 20 hr after their last dose of the 
inhibitor. However, this may also be an indication of sub- 
optimal levels of U-63,557A. Cellular thromboxane bio- 
synthesis is inhibited in a dose-dependent fashion, and 
the dose selected has been shown to maintain plasma 
concentrations U-63,557A above 0.5 pg/ml for 12 hr [23]. 
Serum thromboxane levels drawn immediately prior to 
the animal’s next dose of U-63,557A averaged 30% below 
baseline. Both Freeman et al. [lo] and McDaniel et al. 
[ 151 found a greater decrease in thromboxane levels after 
treatment with U-63,557A 10 mg/kg administered three 
times a day rather than twice a day as in the present 
study, but the time of blood sampling was not reported. 
The aim of the present study was to evaluate the ef- 
fectiveness of various agents in promoting early graft pa- 
tency. Since our previous studies demonstrated 0% 2-week 
patency of 5-mm-i.d. ePTFE aortoiliac grafts without the 
use of antiplatelet agents, both ASA and U-63,557A pro- 
moted the patency of unseeded grafts in the current study. 
These results confirm and extend those of Endean et al. 
[7] who studied vein grafts and McDaniel et al. (151 who 
showed improved 1 week patency of 4-mm-i.d., 4-cm-long 
Dacron and ePTFE grafts implanted in the carotid artery 
of dogs receiving U-63,557A or ASA-dipyridamole com- 
pared to no medication. However, neither Schmidt and 
colleagues [19] nor Freeman et al. [9] found significant 
improvement in the patency of 4-mm-i.d., 6-cm-long Da- 
cron or ePTFE grafts in dogs treated with U-63,557A 
compared to no medication in studies extending 4 to 5 
weeks, perhaps a reflection of the longer grafts utilized 
and the longer period of study. In addition, in our studies, 
as well as in those of others [9, 19, 201, U-63,557A was 
not as effective as ASA in promoting the patency of un- 
seeded grafts. Since the effectiveness of antiplatelet agents 
in maintaining short-term graft patency may be related 
to decreased early platelet deposition [ 21, the reduced ef- 
fectiveness of the thromboxane synthetase inhibitor may 
be due to the accumulation of proaggregatory endoper- 
oxide intermediates PGG2 and PGH2 [14, 18, 231. Inter- 
estingly, Sharp et al. [20] noted a significant improvement 
in the patency of EC-seeded Dacron grafts in dogs re- 
ceiving U-63,557A compared to unmedicated animals, but 
no difference between these groups when studying un- 
seeded grafts. Thus, U-63,557A appears to be capable of 
promoting graft patency until sufficient EC are present 
to maintain graft patency. 
Most graft failures in our study occurred at or after l- 
month postimplantation, and appeared to be secondary 
to intimal hyperplasia at the anastomosis. However, the 
causative factors in anastomotic hyperplasia and partic- 
ularly the relationship between early platelet deposition 
and the development of anastomotic hyperplasia are not 
clearly defined [5]. Although many studies have investi- 
gated the efficacy of antiplatelet agents in promoting pa- 
tency, few studies have assessed their effect on intimal 
hyperplasia of grafts. Our study as well as others suggests 
that ASA with or without dipyridamole may inhibit in- 
timal hyperplasia [9, 16, 171. Studies in our laboratory 
have suggested that ASA is more effective than other an- 
tiplatelet drugs and even other cyclooxygenase inhibitors 
in controlling anastomotic hyperplasia [ 121. However, the 
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method by which ASA reduces intimal thickening is un- 
known. Hansen et al. [13] have shown that both ASA- 
dipyridamole and ticlopidine (an antiaggregating agent) 
reduce platelet deposition on ePTFE grafts, but only 
ASA-dipyridamole decreases intimal hyperplasia and 
improves 3-month patency rates. This suggests that the 
benefit of ASA is not simply due to inhibition of platelet 
deposition. 
Long-term graft patency requires controlling tissue ac- 
cumulation at the anastomoses and in downstream ves- 
sels. Although anastomotic hyperplasia was similar in 
seeded and unseeded grafts in ASA-treated dogs, anas- 
tomotic intimal hyperplasia was significantly reduced in 
seeded grafts compared to that in unseeded grafts in U- 
63,557A-treated animals. This suggests that under certain 
circumstances, the presence of an endothelial surface in 
the graft might contribute to the control of anastomotic 
hyperplasia. The nature of these circumstances and the 
mechanism of such control remain to be elucidated. 
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